Posters

A triple-blind clinical trial study assessing the effect of oral supplementation of lentil in dry eye patients

Poster Details

First Author: M.Nejat IRAN

Co Author(s):    K. Jadidi   M. Rozbehani   S. Pirhadi   M. Naderi           

Abstract Details

Purpose:

To evaluate the effect of lentil on mild to moderate dry eye syndrome.

Setting:

Department of Ophthalmology, Bina Eye Hospital Research Center, Tehran, Iran

Methods:

In this randomized triple-blind clinical trial study, patients with complaint of foreign body sensation , eye burning and/or photophobia referred to Baghiatollah hospital were included. Ophthalmology examination was done and the following scores were recorded for each one: (1) TBUT (tear breakup time test,(2) tear osmolarity , (3) Schirmer 1 test and (4) OSDI (ocular surface disease index) .Then the patients were randomized into 2 groups. After 3 month, the patients were visited again and the tests was repeated again. Patients, researcher and statistician were blinded.

Results:

the mean score of OSDI was 0.22±0.21 before treatment in the interventional group which turns to 0.20±0.18 after treatment (p=0.535) .The mean score of TBUT was 9.62±4.88 seconds before treatment in the interventional group which turns to 12.45±6.32 after three months (p=0.019). The mean score of schirmer test 1 was 7.93±6.71milimeters before treatment in the interventional group which turns to 10.64±9.37 after three months (p=0.086). The mean score of osmolalrity test was 299.38±16.29 miliosmol before treatment in the interventional group which turns to 299.21±12.71 after three months (p=0.297). The mean score of corneal staining with flourcein was 0.69±0.66 before treatment in the interventional group which turns to 0.45±0.50 after three months.(p=0.257).

Conclusions:

There was improvement in all tests but it was statistically significant just in TBUT test. We recommend similar studies with greater sample size and higher dose of capsules in order to see the distinctive effect of this nutrient on dry eye.

Financial Disclosure:

NONE